Kinase News and Research

RSS

Absence of certain proteins for proper cell duplication can lead to cancer

A Purdue University researcher has discovered that the absence of certain proteins needed for proper cell duplication can lead to cancer.

6 Oct 2009

YM BioSciences to acquire Cytopia

Cytopia Limited has today announced that Cytopia and Toronto-based YM BioSciences Inc. ("YM") have signed an exclusive and binding Implementation Agreement ("Agreement") in which it is proposed that YM will acquire all of the issued shares and options in Cytopia.

6 Oct 2009

Study shows that GSK-3 gene determines the total number of neurons required for brain

In populating the growing brain, neural stem cells must strike a delicate balance between two key processes - proliferation, in which the cells multiply to provide plenty of starting materials - and differentiation, in which those materials evolve into functioning neurons.

5 Oct 2009

New study sheds light on memory formation

A new study from the Montreal Neurological Institute and Hospital (The Neuro) of McGill University reveals that different patterns of training and learning lead to different types of memory formation.

5 Oct 2009

Critical biochemical pathways linked to the aging of human muscle identified

A study led by researchers at the University of California, Berkeley, has identified critical biochemical pathways linked to the aging of human muscle. By manipulating these pathways, the researchers were able to turn back the clock on old human muscle, restoring its ability to repair and rebuild itself.

3 Oct 2009

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).

From Thermo Fisher Scientific Inc. 3 Oct 2009

Critical biochemical pathways linked to the aging of human muscle identified

30 Sep 2009

Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor

Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.

26 Sep 2009

New method found for the treatment of pancreatic cancer

For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.

24 Sep 2009

Acetaminophen can prevent age-related problems

Recent studies conducted by Dr. Eric Blough and his colleagues at Marshall University have shown that use of the common pain reliever acetaminophen may help prevent age-associated muscle loss and other conditions.

24 Sep 2009

Lab-on-a-chip performs 1,000 chemical reactions at once

Flasks, beakers, and hot plates may soon be a thing of the past in medicinal chemistry labs. Instead of handling a few experiments on a benchtop, scientists may simply pop a microchip into a computer and instantly run thousands of chemical reactions, with results literally shrinking the lab down to the size of a thumbnail.

From Siemens Healthineers 23 Sep 2009

Sorafenib with chemotherapy for breast cancer patients had a 74% percent improvement in the time they lived

One of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.

23 Sep 2009

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.

23 Sep 2009

Molecule responsible for neuronal branches identifed

The human brain consists of about 100 billion (1011) neurons, which altogether form about 100 trillion (1014) synaptic connections with each other. A crucial mechanism for the generation of this complex wiring pattern is the formation of neuronal branches. The neurobiologists Dr. Hannes Schmidt and Professor Fritz G. Rathjen at the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have now discovered a molecule that regulates this vital process. At the same time they have succeeded in elucidating the signaling cascade induced by this molecule (PNAS, Early Edition, 2009, doi:10.1073).

22 Sep 2009

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).

22 Sep 2009

Clinical trial results of topical INCB18424 inhibitor announced by Incyte Corporation

Incyte Corporation (Nasdaq:INCY) announced positive clinical trial results for a topical formulation of its lead janus kinase (JAK) inhibitor, INCB18424, in psoriasis.

21 Sep 2009

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).

19 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009

Protein kinase Erk3 plays a critical role in intrauterine growth and lung maturation

Dr. Sylvain Meloche, Principal Investigator at the Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al, and his colleagues have uncovered the critical role played by the protein kinase Erk3 in fetal growth potential and lung maturation.

17 Sep 2009

Cellzome's quantitative chemical proteomics platform described in a journal

Cellzome announces today, the publication entitled "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling" is now available online in Nature.

17 Sep 2009

Kinase News and Research

Absence of certain proteins for proper cell duplication can lead to cancer

YM BioSciences to acquire Cytopia

Study shows that GSK-3 gene determines the total number of neurons required for brain

New study sheds light on memory formation

Critical biochemical pathways linked to the aging of human muscle identified

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

Critical biochemical pathways linked to the aging of human muscle identified

Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor

New method found for the treatment of pancreatic cancer

Acetaminophen can prevent age-related problems

Lab-on-a-chip performs 1,000 chemical reactions at once

Sorafenib with chemotherapy for breast cancer patients had a 74% percent improvement in the time they lived

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

Molecule responsible for neuronal branches identifed

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Clinical trial results of topical INCB18424 inhibitor announced by Incyte Corporation

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Protein kinase Erk3 plays a critical role in intrauterine growth and lung maturation

Cellzome's quantitative chemical proteomics platform described in a journal

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News